These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

650 related articles for article (PubMed ID: 32900588)

  • 1. Anti-inflammatory properties of antidiabetic drugs: A "promised land" in the COVID-19 era?
    Katsiki N; Ferrannini E
    J Diabetes Complications; 2020 Dec; 34(12):107723. PubMed ID: 32900588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drugs for type 2 diabetes.
    Med Lett Drugs Ther; 2019 Nov; 61(1584):169-178. PubMed ID: 31770362
    [No Abstract]   [Full Text] [Related]  

  • 3. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials.
    Giugliano D; De Nicola L; Maiorino MI; Bellastella G; Esposito K
    Diabetes Obes Metab; 2019 Aug; 21(8):1790-1800. PubMed ID: 30969018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications.
    Eleftheriadou I; Grigoropoulou P; Liberopoulos E; Liatis S; Kokkinos A; Tentolouris N
    Curr Med Chem; 2018; 25(13):1549-1566. PubMed ID: 28554326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy of Type 2 Diabetes in Patients with SARS-CoV-2 Infection.
    Bielka W; Przezak A; Pawlik A
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
    Nauck MA; Kahle M; Baranov O; Deacon CF; Holst JJ
    Diabetes Obes Metab; 2017 Feb; 19(2):200-207. PubMed ID: 27709794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.
    Russell S
    Int J Clin Pharm; 2013 Apr; 35(2):159-72. PubMed ID: 23263796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular safety outcomes of new antidiabetic therapies.
    LeBras MH; Barry AR; Koshman SL
    Am J Health Syst Pharm; 2017 Jul; 74(13):970-976. PubMed ID: 28483748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Incretin-based therapy for treating patients with type 2 diabetes].
    Jermendy G
    Orv Hetil; 2011 Nov; 152(48):1931-40. PubMed ID: 22071295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I
    Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Drug Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors Based on Target Molecular Binding Occupancy.
    Takayanagi R; Uchida T; Kimura K; Yamada Y
    Biol Pharm Bull; 2018; 41(2):153-157. PubMed ID: 29386477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes.
    Med Lett Drugs Ther; 2019 Feb; 61(1566):26-28. PubMed ID: 30845101
    [No Abstract]   [Full Text] [Related]  

  • 14. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-insulin anti-diabetic agents in patients with type 2 diabetes and COVID-19: A Critical Appraisal of Literature.
    Singh AK; Singh R; Saboo B; Misra A
    Diabetes Metab Syndr; 2021; 15(1):159-167. PubMed ID: 33352455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Therapeutic Approaches in Diabetes.
    Gallwitz B
    Endocr Dev; 2016; 31():43-56. PubMed ID: 26824365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.
    Seferović PM; Coats AJS; Ponikowski P; Filippatos G; Huelsmann M; Jhund PS; Polovina MM; Komajda M; Seferović J; Sari I; Cosentino F; Ambrosio G; Metra M; Piepoli M; Chioncel O; Lund LH; Thum T; De Boer RA; Mullens W; Lopatin Y; Volterrani M; Hill L; Bauersachs J; Lyon A; Petrie MC; Anker S; Rosano GMC
    Eur J Heart Fail; 2020 Feb; 22(2):196-213. PubMed ID: 31816162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Anti-Diabetic Drugs on Fracture Risk: A Systematic Review and Network Meta-Analysis.
    Zhang YS; Zheng YD; Yuan Y; Chen SC; Xie BC
    Front Endocrinol (Lausanne); 2021; 12():735824. PubMed ID: 34721294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
    Mikhail N
    Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.